NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Pristimerin inhibited the expression and translocation of p65, the phosphorylation of IκBα and the activation of IKKα/β, identifying the inhibition of constitutive NF-κB pathway in CRC (20), pancreatic cancer (41), CML (43), ESCC (86), and multiple myeloma tumors (108).